FDA Approves Powdered Treprostinil Inhalation for Pulmonary Hypertension
THE U.S. Food and Drug Administration has approved a novel inhaled formulation of treprostinil for adults with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), adding a new option for improving exercise ability in these patient populations.